Ivan V Pozhidaev

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7773910/publications.pdf

Version: 2024-02-01

1039406 1058022 28 227 9 14 citations h-index g-index papers 41 41 41 238 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. World Journal of Biological Psychiatry, 2017, 18, 239-246.	1.3	28
2	CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. Bulletin of Experimental Biology and Medicine, 2016, 160, 687-690.	0.3	25
3	Prolactin gene polymorphism (\hat{a} ° 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophrenia Research, 2017, 182, 110-114.	1.1	24
4	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. BMC Medical Genetics, 2019, 20, 47.	2.1	17
5	Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression. Frontiers in Pharmacology, 2019, 10, 1462.	1.6	15
6	Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of <i>CHRM1 </i> and <i>CHRM2 </i> muscarinic receptors. World Journal of Biological Psychiatry, 2020, 21, 72-77.	1.3	13
7	NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder. Frontiers in Genetics, 2020, 11, 936.	1.1	13
8	Association between 8 Pâ€glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drugâ€induced hyperprolactinaemia. British Journal of Clinical Pharmacology, 2020, 86, 1827-1835.	1.1	13
9	Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. Journal of Personalized Medicine, 2021, 11, 181.	1.1	11
10	Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 340-346.	0.9	10
11	5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. Frontiers in Molecular Neuroscience, 2020, 13, 63.	1.4	9
12	<p>Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia</p> . The Application of Clinical Genetics, 2020, Volume 13, 97-105.	1.4	7
13	Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. Frontiers in Psychiatry, 2021, 12, 661174.	1.3	7
14	Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1123-1131.	0.4	7
15	Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects. Therapeutic Drug Monitoring, 2020, 42, 325-329.	1.0	6
16	No evidence so far of a major role of <i>AKT1</i> and <i>GSK3B</i> in the pathogenesis of antipsychoticâ€induced tardive dyskinesia. Human Psychopharmacology, 2019, 34, e2685.	0.7	5
17	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatmentâ€free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. Human Psychopharmacology, 2021, , e2826.	0.7	5
18	Association of ANKK1 polymorphism with antipsychoticâ€induced hyperprolactinemia. Human Psychopharmacology, 2020, 35, e2737.	0.7	4

#	Article	IF	CITATIONS
19	Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action. Journal of Personalized Medicine, 2021, 11, 731.	1.1	4
20	Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome. Genes, 2022, 13, 844.	1.0	2
21	Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia. Diagnostics, 2022, 12, 1521.	1.3	1
22	Association Between Prolactin Gene Polymorphism (–1149 G/T) and Hyperprolactinemia in Anti-psychotic Treated Patients with Schizophrenia. European Psychiatry, 2017, 41, S267-S267.	0.1	0
23	Association of polymorphism in the dopamine receptors and transporter genes with hyperprolactinemia in patients with schizophrenia. European Neuropsychopharmacology, 2017, 27, S923-S924.	0.3	0
24	Tardive dyskinesia in schizophrenia: Gene polymorphisms of muscarinic and adrenergic receptors. European Neuropsychopharmacology, 2019, 29, S117-S118.	0.3	0
25	The study of dopamine receptor genes in patients with schizophrenia. European Neuropsychopharmacology, 2019, 29, S410-S411.	0.3	O
26	P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients. European Neuropsychopharmacology, 2020, 40, S331-S332.	0.3	0
27	COMT gene polymorphism and antipsychotic- induced hyperprolactinemia in schizophrenia patients. , 2020, , .		O
28	Association of Ð¡ĐžĐœĐ¢ gene polymorphisms with Parkinson's disease. Bulletin of Siberian Medicine, 2017, 70-78.	16 0.1	0